CA2155130C - Xanthine derivatives as adenosine a1 receptor antagonists - Google Patents

Xanthine derivatives as adenosine a1 receptor antagonists

Info

Publication number
CA2155130C
CA2155130C CA002155130A CA2155130A CA2155130C CA 2155130 C CA2155130 C CA 2155130C CA 002155130 A CA002155130 A CA 002155130A CA 2155130 A CA2155130 A CA 2155130A CA 2155130 C CA2155130 C CA 2155130C
Authority
CA
Canada
Prior art keywords
dione
dihydro
purine
dipropyl
phenylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002155130A
Other languages
English (en)
French (fr)
Other versions
CA2155130A1 (en
Inventor
Janice M Hitchcock
Stephen M. Sorenson
Mark W. Dudley
Norton P. Peet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA2155130A1 publication Critical patent/CA2155130A1/en
Publication of CA2155130C publication Critical patent/CA2155130C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002155130A 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists Expired - Fee Related CA2155130C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26
US08/023,501 1993-02-26

Publications (2)

Publication Number Publication Date
CA2155130A1 CA2155130A1 (en) 1994-09-01
CA2155130C true CA2155130C (en) 1994-09-01

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155130A Expired - Fee Related CA2155130C (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists

Country Status (19)

Country Link
US (1) US5840729A (cg-RX-API-DMAC7.html)
EP (1) EP0686155B1 (cg-RX-API-DMAC7.html)
JP (1) JPH08512281A (cg-RX-API-DMAC7.html)
KR (1) KR100315898B1 (cg-RX-API-DMAC7.html)
CN (1) CN1041418C (cg-RX-API-DMAC7.html)
AT (1) ATE169019T1 (cg-RX-API-DMAC7.html)
AU (1) AU680241B2 (cg-RX-API-DMAC7.html)
CA (1) CA2155130C (cg-RX-API-DMAC7.html)
DE (1) DE69412073T2 (cg-RX-API-DMAC7.html)
DK (1) DK0686155T3 (cg-RX-API-DMAC7.html)
ES (1) ES2120025T3 (cg-RX-API-DMAC7.html)
HU (1) HUT72677A (cg-RX-API-DMAC7.html)
IL (1) IL108750A (cg-RX-API-DMAC7.html)
MX (1) MX9401406A (cg-RX-API-DMAC7.html)
NO (1) NO311920B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ262984A (cg-RX-API-DMAC7.html)
TW (1) TW261532B (cg-RX-API-DMAC7.html)
WO (1) WO1994019349A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA941176B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
ATE446298T1 (de) 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
EA007468B1 (ru) 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
US6846958B2 (en) * 2002-05-15 2005-01-25 Genzyme Corporation Synthesis of benzimidate from benzoic acid
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
BRPI0417241A (pt) * 2003-12-09 2007-03-06 Kyowa Hakko Kogyo Kk agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU680241B2 (en) 1997-07-24
EP0686155B1 (en) 1998-07-29
ZA941176B (en) 1994-09-20
DK0686155T3 (da) 1999-02-01
DE69412073T2 (de) 1999-02-18
CA2155130A1 (en) 1994-09-01
JPH08512281A (ja) 1996-12-24
CN1041418C (zh) 1998-12-30
NO953353L (no) 1995-08-25
MX9401406A (es) 1994-08-31
EP0686155A1 (en) 1995-12-13
ES2120025T3 (es) 1998-10-16
TW261532B (cg-RX-API-DMAC7.html) 1995-11-01
KR100315898B1 (ko) 2002-02-28
CN1118599A (zh) 1996-03-13
ATE169019T1 (de) 1998-08-15
NZ262984A (en) 1997-05-26
US5840729A (en) 1998-11-24
HU9502495D0 (en) 1995-10-30
DE69412073D1 (de) 1998-09-03
WO1994019349A1 (en) 1994-09-01
NO311920B1 (no) 2002-02-18
IL108750A0 (en) 1994-05-30
HUT72677A (en) 1996-05-28
NO953353D0 (no) 1995-08-25
AU6296894A (en) 1994-09-14
IL108750A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
US6545000B1 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivatives
CA2155130C (en) Xanthine derivatives as adenosine a1 receptor antagonists
JPH06211856A (ja) パーキンソン氏病治療剤
JP2005516975A (ja) ８−ヘテロアリールキサンチンアデノシンａ２ｂ受容体アンタゴニスト
PL217269B1 (pl) Pochodne triazoliloimidazopirydyny i triazolilopuryny, zawierająca je kompozycja farmaceutyczna, ich zastosowanie, sposób ich otrzymywania oraz związki pośrednie wykorzystywane w tym sposobie
HUP0200938A2 (en) Purine derivatives having phosphodiesterase iv inhibition activity and medicaments containing them
US5047534A (en) Selective adenosine receptor agents
AU676323B2 (en) 8-substituted xanthines as selective adenosine receptor agents
JPWO2000017201A1 (ja) ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
JPWO2001032182A1 (ja) 摂食障害治療剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20050127